A phase III randomized, controlled trial of Myocet®, trastuzumab and paclitaxel versus trastuzumab and paclitaxel for first-line therapy of metastatic breast cancer
A phase III randomized, controlled trial of Myocet®, trastuzumab and paclitaxel versus trastuzumab and paclitaxel for first-line therapy of metastatic breast cancer